TP53 and cancer: CTM inhibits growth of cancer cells harboring mutant p53 R175H in vitro and in vivo, binds to Hsp40 and increases the binding capacity of Hsp40 to the p53 R175H mutant protein, causing a potential conformational change to a wild-type-like p53 [182].